27. Broder A, Khattri S, Patel R, Putterman C. Undertreatment of Disease Activity in Systemic Lupus Erythematosus Patients with Endstage Renal Failure Is Associated with Increased All-cause Mortality. J Rheumatol. Nov 2011;38(11):2382-9.
28. Mosca M, Tani C, Carli L, Bombardieri S. Glucocorticoids in systemic lupus erythematosus. Clin Exp Rheumatol. Sep-Oct 2011;29(5 Suppl 68):S126-9.
29. Bramham K, Hunt BJ, Bewley S. Pregnancy outcomes in systemic lupus erythematosus with and without previous nephritis. J Rheumatol. Sep 2011;38(9):1906-13.
30. Vinet E, Clarke AE, Gordon C, Urowitz MB, Hanly JG, Pineau CA, et al. Decreased live births in women with systemic lupus erythematosus. Arthritis Care Res (Hoboken). Jul 2011;63(7):1068-72.
31. Dillon S, Aggarwal R, Harding JW. Klinefelter’s syndrome (47,XXY) among men with systemic lupus erythematosus. Acta Paediatr. Jun 2011;100(6):819-23.
32. Pineles D, Valente A, Warren B, Peterson MG, Lehman TJ, Moorthy LN. Worldwide incidence and prevalence of pediatric onset systemic lupus erythematosus. Lupus. Oct 2011;20(11):1187-92.
33. Jaeggi E, Laskin C, Hamilton R, Kingdom J, Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol. Jun 15 2010;55(24):2778-84.
34. Hu W, Ren H. A meta-analysis of the association of IRF5 polymorphism with systemic lupus erythematosus. Int J Immunogenet. Oct 2011;38(5):411-7.
35. Peniche DM, González SC. Neumonitis secundaria a lupus eritematoso sistémico. Rev Factad Med UNAM. 2014 Oct 57(5): 44-50
36. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum. Jan 2010;62(1):211-21.
37. Dooley MA, Jayne D, Ginzler EM. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. Nov 17 2011;365(20):1886-95.
38. Houssiau FA, D’Cruz D, Sangle S. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. Dec 2010;69(12):2083-9.
39. Lo MS, Tsokos GC. T cells in systemic lupus erythematosus: progress toward targeted therapy [August 2011]. The Rheumatologist [Internet]. Accessed August 10, 2012. Disponible en http://tinyurl.com/tcellsSLE.